A 52-week Treatment, Randomized, Double-blind, Placebo-controlled, With Open-label Tiotropium, Parallel-group Study to Assess the Efficacy, Safety, and Tolerability of Glycopyrronium Bromide (NVA237) in Patients With Chronic Obstructive Pulmonary Disease

Trial Profile

A 52-week Treatment, Randomized, Double-blind, Placebo-controlled, With Open-label Tiotropium, Parallel-group Study to Assess the Efficacy, Safety, and Tolerability of Glycopyrronium Bromide (NVA237) in Patients With Chronic Obstructive Pulmonary Disease

Completed
Phase of Trial: Phase III

Latest Information Update: 03 May 2016

At a glance

  • Drugs Glycopyrrolate (Primary) ; Tiotropium bromide
  • Indications Chronic obstructive pulmonary disease
  • Focus Pharmacogenomic; Registrational; Therapeutic Use
  • Acronyms GLOW-2
  • Sponsors Novartis
  • Most Recent Events

    • 05 Sep 2012 Results from a pooled analysis of GLOW 1 and GLOW 2 presented at the 22nd Annual Congress of the European Respiratory Society.
    • 03 Sep 2012 Results from pooled analyses of GLOW-1 and GLOW-2 have been presented at the 2012 Annual Congress of the European Society of Cardiology (ESC-2012) according to a Novartis media release. Results were also summarised in the media release.
    • 26 Jul 2012 Additional trial locations added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top